187 related articles for article (PubMed ID: 37775297)
1. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren H; Berry S; Malkin SJP; Hunt B; Bain S
BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
[TBL] [Abstract][Full Text] [Related]
3. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B
Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
[TBL] [Abstract][Full Text] [Related]
9. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
[TBL] [Abstract][Full Text] [Related]
10. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Viljoen A; Chubb B; Malkin SJP; Berry S; Hunt B; Bain SC
Eur J Health Econ; 2023 Aug; 24(6):895-907. PubMed ID: 36114904
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
[TBL] [Abstract][Full Text] [Related]
13. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
14. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
15. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
Evans M; Berry S; Malkin SJP; Hunt B; Sharma A
Diabetes Ther; 2023 Jun; 14(6):1005-1021. PubMed ID: 37120480
[TBL] [Abstract][Full Text] [Related]
17. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
